P
P. Valagussa
Researcher at University of Milan
Publications - 83
Citations - 6626
P. Valagussa is an academic researcher from University of Milan. The author has contributed to research in topics: Breast cancer & ABVD. The author has an hindex of 39, co-authored 83 publications receiving 6437 citations. Previous affiliations of P. Valagussa include European Institute of Oncology.
Papers
More filters
Journal ArticleDOI
Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
G. Bonadonna,Ercole Brusamolino,P. Valagussa,Andrea Rossi,Brugnatelli L,Cristina Brambilla,De Lena M,Gabriele Tancini,Emilio Bajetta,Renato Musumeci,Umberto Veronesi +10 more
TL;DR: Long-term chemotherapy produced an acceptable toxicity, thus allowing the administration of a high percentage of drug dosage, and the effect of this therapy on survival and possible long-term side effects remain unknown.
Journal ArticleDOI
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
Alessandro M. Gianni,Marco Bregni,Salvatore Siena,Cristina Brambilla,Di Nicola M,F. Lombardi,Lorenza Gandola,Corrado Tarella,Alessandro Pileri,Fernando Ravagnani,P. Valagussa,G. Bonadonna +11 more
TL;DR: High-dose sequential therapy is superior to standard-dose MACOP-B for patients with diffuse large-cell lymphoma of the B-cell type and overall survival at seven years is marginally significant.
Journal ArticleDOI
Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.
Armando Santoro,G. Bonadonna,P. Valagussa,Roberto Zucali,Simonetta Viviani,F. Villani,A.M. Pagnoni,Valeria Bonfante,Renato Musumeci,Flavio Crippa +9 more
TL;DR: ABVD followed by extensive irradiation represents a valid therapeutic alternative to the widely used alkylating agent-containing regimens plus radiotherapy, and the comparative iatrogenic morbidity showed that irreversible gonadal dysfunction as well as acute leukemia occurred only in patients subjected to MOPP.
Journal ArticleDOI
The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial.
TL;DR: It is shown that the removal of internal mammary nodes does not improve the survival of patients treated for breast carcinoma after 30 years of follow-up, and this finding supports the theory that treatment of regional nodesdoes not influence the survivalof cancer patients.
Journal ArticleDOI
Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
TL;DR: The incidence of second neoplasms can be markedly decreased by deleting from potentially curative therapy certain drugs such as alkylating agents, procarbazine, and nitrosourea derivatives.